Protara Therapeutics Inc(TARA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:01 PM ET (Korea 10/29 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.35 | Insider Own | 11.68% | Shs Outstand | 59.1M | Perf Week | -0.4% |
| Market Cap | 0.15B | Forward P/E | - | EPS next Y | -17.82% | Insider Trans | -3.03% | Shs Float | 52.2M | Perf Month | -22.43% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.37 | Inst Own | 69.3% | Short Float | 11.68% | Perf Quarter | -38.21% |
| Income | -0.07B | P/S | - | EPS this Y | -3.52% | Inst Trans | 5.22% | Short Ratio | 6.43 | Perf Half Y | -51.84% |
| Sales | 0.00B | P/B | 0.91 | EPS next 5Y | 23.07% | ROA | -42.05% | Short Interest | 6.09M | Perf YTD | -53.28% |
| Book/sh | 2.73 | P/C | 1.03 | EPS past 3/5Y | 38.83% 22.18% | ROE | -45.8% | 52W High | -68.16% ($7.82) | Perf Year | -51.08% |
| Cash/sh | 2.41 | P/FCF | - | Sales past 3/5Y | - | ROIC | -43.01% | 52W Low | 9.21% ($2.28) | Perf 3Y | 105.79% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 17.06% | Gross Margin | - | Volatility(W/M) | 6.05% 7.2% | Perf 5Y | -64.48% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.17 | Perf 10Y | -99.37% |
| Dividend Ex-Date | - | Quick Ratio | 10.97 | EPS Q/Q | -0.37% | Profit Margin | - | RSI (14) | 38.17 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.97 | Sales Q/Q | - | SMA20 | -1.78% ($2.54) | Beta | 1.51 | Target Price | $25.71 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/11 | SMA50 | -23.29% ($3.25) | Rel Volume | 1.27 | Prev Close | $2.47 |
| Employees | 51 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -10.53% - | SMA200 | -45.74% ($4.59) | Avg Volume(3M) | 0.95M | Price | $2.49 |
| IPO | 2014/10/22 | Option/Short | Yes/Yes | Trades | 4043 | Volume | 1,204,564 | Change | 0.81% |
🧬 A US clinical-stage biotech company developing novel drug candidates for patients with non-muscle-invasive bladder cancer, lymphatic malformations, and intravenous nutrition dependence. The company operates its pipeline around two main pillars: a cell-based immunotherapy candidate and an intravenous choline chloride therapy, and remains a development-stage company with no commercialized products yet.
Over the past 1 year, on the lower side
68% below its 1-year high.
Traded more than usual. That is 127% of its average volume.
TARA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -3.5% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -64.5%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 69.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #329 of 594 in the industry
Based on market cap of $147M.
CUE#327 Cue Biopharma Inc $154M PER - 
MENS#328 Jyong Biotech Ltd $152M PER - TARA#329 Protara Therapeutics Inc $147M PER - 
NBP#330 NovaBridge Biosciences ADR $146M PER - 
VRXA#331 Veraxa Biotech AG $145M PER 4.6 
FAQ
What kind of company is TARA?
TARA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TARA?
The market cap of TARA is approximately $147M, ranking 4,246 within its sector.
What is the 52-week high and low for TARA?
TARA has recorded a 52-week high of $7.82 and a low of $2.28.
